Identifai Genetics Will Debut on ASX in October
The Israeli biotech company will launch its initial public offering on October 13, 2026, targeting a $38.4 million valuation.
Updated on Sept. 25, 2026 in Biotech
Live Poll
Do you trust that new prenatal genetic testing technologies provide more medical benefits than risks?
Israeli biotech firm Identifai Genetics will list on the Australian stock exchange on October 13, 2026, raising $10 million through an initial public offering. The company is currently valued at $38.4 million as it seeks to expand its genetic screening capabilities.
Why it matters
The company aims to enable early treatment of genetic conditions before symptoms emerge, targeting more than 280 inherited diseases. This technology allows for medical intervention at critical stages in utero or immediately after birth.
The Windrose test screens for 280 genetic conditions using maternal blood drawn at nine weeks of pregnancy. It utilizes a machine learning algorithm to compare fetal cell-free DNA against maternal DNA while scanning the entire genome.
The players
Identifai Genetics
An Israeli biotechnology company that utilizes machine learning algorithms to conduct genome-wide fetal genetic screenings.
Professor Noam Shomron
He is the researcher whose work founded the technological basis for the company's genetic diagnostic tests.
The details
Founded on research by Professor Noam Shomron, the firm identifies 54 conditions treatable in utero and 267 conditions that can be managed within the first week of life. The company is currently conducting a 600-patient clinical validation trial to support its diagnostic methodology.
Timeline
2012: Non-invasive pregnancy tests began being offered.
October 13, 2026: Identifai Genetics will debut on the ASX.
Late 2027: Clinical validation trial is expected to conclude.
The Tech Race
The emergence of Identifai Genetics represents the latest evolution in the market for non-invasive prenatal testing (NIPT) which has expanded since 2012. This technology advances the sector by shifting focus from simple screening toward active detection of treatable conditions.
The Windrose test provides a standardized way for expectant parents to identify potential health conditions at just nine weeks of pregnancy. This early information allows families and physicians to coordinate care plans for conditions treatable in utero or immediately upon birth.
The takeaway
Advancements in genetic screening are increasingly moving toward actionable outcomes that allow for earlier medical interventions. Investors and healthcare providers are closely watching how these diagnostic tools integrate into standardized prenatal care protocols.
What happens next
The company expects to conclude its 600-patient clinical validation trial in the United States by late 2027.
Further reading
Learn more about the latest innovations in Biotech.
Source note: This article includes information reported by The Border Mail.
Live Poll
Do you trust that new prenatal genetic testing technologies provide more medical benefits than risks?
